Optimizing prophylactic treatment of migraine: Subtypes and patient matching

Therapeutics and Clinical Risk Management

Volumn 4, Issue 5, 2008, Pages 1061-1078

  Dib, Michel ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Diagnosis; Migraine; Prophylaxis; Subtypes; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CYPROHEPTADINE; DICLOFENAC; DIHYDROERGOTAMINE; ERGOT ALKALOID; ESTROGEN; FLUNARIZINE; GESTAGEN; IBUPROFEN; KETOPROFEN; METHYSERGIDE; METOCLOPRAMIDE; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PIZOTIFEN; PLACEBO; PROPRANOLOL; SEROTONIN ANTAGONIST; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNINDEXED DRUG; VALPROIC ACID; ZOLMITRIPTAN;

ADRENERGIC SYSTEM; CAUSAL ATTRIBUTION; CHRONIC DISEASE; CHRONIC TENSION HEADACHE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; COMPLICATED MIGRAINE; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DISEASE EXACERBATION; DIZZINESS; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTROGEN THERAPY; FAMILIAL HEMIPLEGIC MIGRAINE; FATIGUE; HEADACHE; HUMAN; INSOMNIA; LOW DRUG DOSE; MENSTRUAL MIGRAINE; MIGRAINE; MONOTHERAPY; MORBIDITY; NAUSEA; NONHUMAN; PATHOGENESIS; PLEURAL FIBROSIS; PRIMARY PREVENTION; PROCESS OPTIMIZATION; RECOMMENDED DRUG DOSE; RETROPERITONEAL FIBROSIS; REVIEW; RISK FACTOR; SEROTONINERGIC SYSTEM; SIDE EFFECT; SOMNOLENCE; TRANSFORMED MIGRAINE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 56749140659     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (257)

1. Abu-Arefeh I, Russell G. 1994. Prevalence of headache and migraine in schoolchildren. Br Med J, 309:765-9.
2. Adelman JU, Belsey J. 2003. Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. J Manag Care Pharm, 9:45-52.
3. Adelman LC, Adelman JU, Von Seggern R, et al. 2000. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache, 40:572-80.
4. Adly C, Straumanis J, Chesson A. 1992. Fluoxetine prophylaxis of migraine. Headache, 32:101-4.
5. Andersson KE, Vinge E. 1990. Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs, 39:355-73.
6. Andersson PG, Petersen EN. 1981. Propranolol and femoxetine, a HT-uptake inhibitor, in migraine prophylaxis. A double-blind crossover study. Acta Neurol Scand, 64:280-8.
7. Annequin D, Tourniaire B, Massiou H. 2000. Migraine and headache in childhood and adolescence. Pediatr Clin North Am, 47:617-31.
8. Ansell E, Fazzone T, Festenstein R, et al. 1988. Nimodipine in migraine prophylaxis. Cephalalgia, 8:269-72.
9. Bank J. 1994. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache, 34:476-8.
10. Bellavance AJ, Meloche JP. 1990. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache, 30:710-5.
11. Belsey JD. 2004. Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials. Curr Med Res Opin, 20:659-69.
12. Bigal ME, Bordini CA, Speciali JG. 2002. [Intramuscular diclofenac in the acute treatment of migraine: a double-blind placebo controlled study]. Arq Neuropsiquiatr, 60:410-5.
13. Bille B, Ludvigsson J, Sanner G. 1977. Prophylaxis of migraine in children. Headache, 17:61-3.
14. Bonuso S, Di Stasio E, Barone P, et al. 1983. Timed-release dihydroergotamine in the prophylaxis of mixed headache. A study versus amitriptyline. Cephalalgia, 3(Suppl 1):175-8.
15. Bordini CA, Arruda MA, Ciciarelli MC, et al. 1997. Propranolol vs flunarizine vs flunarizine plus propranolol in migraine without aura prophylaxis. A double-blind trial. Arq Neuropsiquiatr, 55:536-41.
16. Boureau F, Joubert JM, Lasserre V, et al. 1994. Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia, 14:156-61.
17. Bousser MG, Chick J, Fuseau E, et al. 1988. Combined low-dose acetylsalicylic acid and dihydroergotamine in migraine prophylaxis. A double-blind, placebo-controlled crossover study. Cephalalgia, 8:187-92.
18. Bowyer SM, Mason K.M, Moran JE, et al. 2005. Cortical hyperexcitability in migraine patients before and after sodium valproate treatment. J Clin Neurophysiol, 22:65-7.
19. Bradley WG, Hudgson P, Foster JB, et al. 1968. Double-blind controlled trial of a micronized preparation of flumedroxone (Demigran) in prophylaxis of migraine. Br Med J, 3:531-3.
20. Brandes JL, Saper JR, Diamond M, et al. 2004. Topiramate for migraine prevention: a randomized controlled trial. JAMA, 291:965-73.
21. Brennum J, Brinck T, Schriver L, et al. 1996. Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. Eur J Neurol, 3:23-28.
22. Bulut S, Berilgen MS, Baran A, et al. 2004. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg, 107:44-8.
23. Burke BE, Olson RD, Cusack BJ. 2002. Randomized, controlled trial of phytoestrogen in the prophylactic treatment of menstrual migraine. Biomed Pharmacother, 56:283-8.
24. Bussone G, Cerbo R, Martucci N, et al. 1999. Alpha-dihydroergocryptine in the prophylaxis of migraine: a multicenter double-blind study versus flunarizine. Headache, 39:426-31.
25. + channel activity and inhibitory synaptic transmission. Proc Natl Acad Sci U S A, 102:2590-5.
26. Carey MP, Billing AE, Fry JP. 1992. Fluctuations in responses to diazepam during the oestrous cycle in the mouse. Pharmacol Biochem Behav, 41:719-25.
27. Castillo J, Munoz P, Guitera V, et al. 1999. Epidemiology of chronic daily headache in the general population. Headache, 39:190-6.
28. Chabriat H, Joire JE, Danchot J, et al. 1994. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia, 14:297-300.
29. Chronicle E, Mulleners W. 2004. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev, 3:CD003226.
30. Codispoti JR, Prior MJ, Fu M, et al. 2001. Efficacy of nonprescription doses of ibuprofen for treating migraine headache, a randomized controlled trial. Headache, 41:665-79.
31. Colombo B, Annovazzi PO, Comi G. 2004. Therapy of primary headaches: the role of antidepressants. Neurol Sci, 25(Suppl 3):S171-5.
32. Couturier EG, Bomhof MA, Neven AK, et al. 2003. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia, 23:302-8.
33. d'Amato CC, Pizza V, Marmolo T, et al. 1999. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache, 39:716-9.
34. D'Andrea G, Granella F, Cadaldini M, et al. 1999. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia, 19:64-6.
35. Dahlof C, Bjorkman R. 1993. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia, 13:117-23.
36. De Benedittis G, Massei R. 1985. Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs placebo. J Neurosurg Sci, 29:239-48.
37. de Coster J. 1976. [Oxetorone in the treatment of migrainous cephalalgia]. Schweiz Rundsch Med Prax, 65:879-82.
38. de Lignieres B, Bousser MG. 1992. Migraine. Lancet, 340:61-2.
39. de Lignieres B, Vincens M, Mauvais-Jarvis P, et al. 1986. Prevention of menstrual migraine by percutaneous oestradiol. Br Med J (Clin Res Ed), 293:1540.
40. Dennerstein L, Morse C, Burrows G, et al. 1988. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol, 2:113-20.
41. Di Trapani G, Mei D, Marra C, et al. 2000. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter, 151:145-8.
42. Diaz-Veliz G, Butron S, Benavides MS, et al. 2000. Gender, estrous cycle, ovariectomy, and ovarian hormones influence the effects of diazepam on avoidance conditioning in rats. Pharmacol Biochem Behav, 66:887-92.
43. Dib M, Massiou H, Weber M, et al. 2002. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology, 58:1660-5.
44. Diener HC. 1997. [Migraine-diagnosis, differential diagnosis and therapy]. Ther Umsch, 54:64-70.
45. Diener HC. 1999. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia, 19:581-8; discussion 542.
46. Diener HC, Brune K, Gerber WD, et al. 1998. [Treatment of migraine attacks and migraine prophylaxis: recommendations of the German Migraine and Headache Society]. Med Monatsschr Pharm, 21:30-9.
47. Diener HC, Bussone G, de Liano H, et al. 2004a. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia, 24:947-54.
48. Diener HC, Foh M, Iaccarino C, et al. 1996. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group. Cephalalgia, 16:441-7.
49. Diener HC, Krupp P, Schmitt T, et al. 2001. Cyclandelate in the prophylaxis of migraine: a placebo-controlled study. Cephalalgia, 21:66-70.
50. Diener HC, Tfelt-Hansen P, Dahlof C, et al. 2004b. Topiramate in migraine prophylaxis - results from a placebo-controlled trial with propranolol as an active control. J Neurol, 251:943-50.
51. Doenicke A, Brand J, Perrin VL. 1988. Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet, 1:1309-11.
52. Dowson AJ, Dodick DW, Limmroth V. 2005. Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis. CNS Drugs, 19:483-97.
53. Dowson AJ, Lipscombe S, Sender J, et al. 2002. New guidelines for the management of migraine in primary care. Curr Med Res Opin, 18:414-39.
54. Drake M, Greathouse N, Armentbright A, et al. 2001. Levetiracetam for preventive treatment of migraine [abstract]. Cephalalgia, 21:373.
55. Drake M, Kay A, Knapp M, et al. 1999. An open-label trial of tiagabine for migraine prophylaxis [abstract]. Headache, 39:352.
56. Drake ME, Greathouse NI, Armentbright AD, et al. 2001. Preventive treatment of migraine with zonisamide [abstract]. Cephalalgia, 21:374.
57. Dufresne JJ. 1978. [Double-blind study of oxetorone in patients with migraine or migrainous headache]. Schweiz Rundsch Med Prax, 67:1148-52.
58. Edwards KR, Norton J, Behnke M. 2001. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache, 41:976-80.
59. Edwards KR, Potter DL, Wu SC, et al. 2003. Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. CNS Spectr, 8:428-32.
60. Ekbom K. 1975. Alprenolol for migraine prophylaxis. Headache, 15:129-32.
61. Ekbom K, Zetterman M. 1977. Oxprenolol in the treatment of migraine. Acta Neurol Scand, 56:181-4.
62. Elkind AH, Friedman AP, Bachman A, et al. 1968. Silent retroperitoneal fibrosis associated with methysergide therapy. JAMA, 206:1041-4.
63. Ensink FB. 1991. Subcutaneous sumatriptan in the acute treatment of migraine. Sumatriptan International Study Group. J Neurol, 238(Suppl 1):S66-9.
64. Epstein MT, Hockaday JM, Hockaday TD. 1975. Migraine and reporoductive hormones throughout the menstrual cycle. Lancet, 1:543-8.
65. Facchinetti F, Nappi RE, Tirelli A, et al. 2002. Hormone supplementation differently affects migraine in postmenopausal women. Headache, 42:924-9.
66. Ferrante F, Fusco E, Calabresi P, et al. 2004. Phyto-oestrogens in the prophylaxis of menstrual migraine. Clin Neuropharmacol, 27:137-40.
67. Ferrari MD, Roan KI, Lipton RB, et al. 2001. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet, 358:1668-75.
68. Ferrari MD, Saxena PR. 1992. Clinical effects and mechanism of action of sumatriptan in migraine. Clin Neurol Neurosurg, 94 Suppl:S73-7.
69. Ferrari MD, Wilkinson M, Hirt D, et al. 1991. Efficacy of ICS 205-930, a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, in the prevention of migraine attacks. A complex answer to a Simple question. ICS 205-930 Migraine Study Group. Pain, 45:283-91.
70. Florence J. 1978. [Clinical study of oxetorone in catamenial migraine. Comparison of two posological diagrams]. Schweiz Rundsch Med Prax, 67:1323-7.
71. Forssman B, Lindblad CJ, Zbornikova V. 1983. Atenolol for migraine prophylaxis. Headache, 23:188-90.
72. Frediani F, Grazzi L, Zanotti A, et al. 1991. Dihydroergokryptine versus dihydroergotamine in migraine prophylaxis: a double-blind clinical trial. Cephalalgia, 11:117-21.
73. Freitag F, Diamond S, Solomon G. 1999. The prophylaxis of migraine with the GABA-agonist tiagabine: a clinical report [abstract]. Cephalalgia, 19:354.
74. Freitag FG, Collins SD, Carlson HA, et al. 2002. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology, 58:1652-9.
75. Freitag FG, Diamond S. 1984. Nadolol and placebo comparison study in the prophylactic treatment of migraine. J Am Osteopath Assoc, 84:343-7.
76. Galiano L, Matías-Guiu J, Horga J, et al. 1993. Dotarizine: a double-blind trial in propylactic treatment of migraine. Cephalalgia, 13(Suppl 13):251.
77. Gawel MJ, Kreeft J, Nelson RF, et al. 1992. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci, 19:340-5.
78. Gelmers HJ. 1983. Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. Headache, 23:106-9.
79. Geraud G, Compagnon A, Rossi A. 2002. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol, 47:88-98.
80. Geraud G, Lanteri-Minet M, Lucas C, et al. 2004. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther, 26:1305-18.
81. Gillies D, Sills M, Forsythe I. 1986. Pizotifen (Sanomigran) in childhood migraine. A double-blind controlled trial. Eur Neurol, 25:32-5.
82. Goadsby PJ, Dodick DW, Ferrari MD, et al. 2004. TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. Acta Neurol Scand, 110:137-43.
83. Gomersall JD, Stuart A. 1973. Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry, 36:684-90.
84. Granella F, Sances G, Allais G, et al. 2004. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia, 24:707-16.
85. Granella F, Sances G, Zanferrari C, et al. 1993. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache, 33:385-9.
86. Grotemeyer KH, Schlake HP, Husstedt IW. 1988. [Prevention of migraine with metoprolol and flunarizine. A double-blind crossover study]. Nervenarzt, 59:549-52.
87. Hamalainen ML, Hoppu K, Valkeila E, et al. 1997. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology, 48:103-7.
88. Havanka-Kanniainen H, Hokkanen E, Myllyla VV. 1985. Efficacy of nimodipine in the prophylaxis of migraine. Cephalalgia, 5:39-43.
89. [HCCIHS] Headache Classification Committee of the International Headache Society. 1988. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia, 8(Suppl 7):1-96.
90. [HCCIHS] Headache Classification Committee of the International Headache Society. 2004. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Second Edition. Cephalalgia, 24(Suppl 1):1-160.
91. Henry P, Auray JP, Gaudin AF, et al. 2002. Prevalence and clinical characteristics of migraine in France. Neurology, 59:232-7.
92. Henry P, Hiesse-Provost O, Dillenschneider A, et al. 1995. [Efficacy and tolerance of an effervescent aspirin-metoclopramide combination in the treatment of a migraine attack. Randomized double-blind study using a placebo]. Presse Med, 24:254-8.
93. Hering R, Kuritzky A. 1992. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia, 12:81-4.
94. Herrmann WM, Kristof M, Sastre M, et al. 1978. Preventive treatment of migraine headache with a new isoergolenyl derivative. J Int Med Res, 6:476-82.
95. HolroydKA, Penzien DB, Cordingley GE. 1991. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache, 31:333-40.
96. International Headache Society Committee on Clinical Trials in Migraine. 1991. Guidelines for controlled trials of drugs in migraine. First edition. Cephalalgia, 11:1-12.
97. Jacobs H. 1972. A trial of opipramol in the treatment of migraine. J Neurol Neurosurg Psychiatry, 35:500-4.
98. Jensen R, Brinck T, Olesen J. 1994. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology, 44:647-51.
99. Jimenez-Hernandez MD, Torrecillas Narvaez MD, Friera Acebal G. 2002. [Effectiveness and safety of gabapentin in the preventive treatment of migraine]. Rev Neurol, 35:603-6.
100. Johannsson V, Nilsson LR, Widelius T, et al. 1987. Atenolol in migraine prophylaxis a double-blind cross-over multicentre study. Headache, 27:372-4.
101. Jones MW. 1998. Topiramate - safety and tolerability. Can J Neurol Sci, 25:S13-5.
102. Kangasniemi P, Andersen AR, Andersson PG, et al. 1987. Classic migraine: effective prophylaxis with metoprolol. Cephalalgia, 7:231-8.
103. Kangasniemi P, Hedman C. 1984. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia, 4:91-6.
104. Kangasniemi PJ, Nyrke T, Lang AH, et al. 1983. Femoxetine-a new 5-HT uptake inhibitor - and propranolol in the prophylactic treatment of migraine. Acta Neurol Scand, 68:262-7.
105. Kaniecki RG. 1997. A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol, 54:1141-5.
106. Karachalios GN, Fotiadou A, Chrisikos N, et al. 1992. Treatment of acute migraine attack with diclofenac sodium: a double-blind study. Headache, 32:98-100.
107. Kass B, Nestvold K. 1980. Propranolol (Inderal) and clonidine (Catapressan) in the prophylactic treatment of migraine. A comparative trial. Acta Neurol Scand, 61:351-6.
108. Kavuk I, Katsarava Z, Selekler M, et al. 2004. Clinical features and therapy of medication overuse headache. Eur J Med Res, 9:565-9.
109. Kellstein DE, Lipton RB, Geetha R, et al. 2000. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia, 20:233-43.
110. Klapper J. 1997. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia, 17:103-8.
111. Kloster R, Nestvold K, Vilming ST. 1992. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia, 12:169-71; discussion 128.
112. Kozubski W, Prusinski A. 1999. [Controlled study of iprazochrome effectiveness (Divascan) in prophylactic treatment of migraine]. Neurol Neurochir Pol, 33:369-76.
113. + channel kinetics. J Biol Chem, 273:5586-90.
114. +) channel kinetics. J Biol Chem, 275:9239-43.
115. Krusz J. 2001a. Levetiracetam as prophylaxis for resistant headaches [abstract]. Cephalalgia, 21:373.
116. Krusz J. 2001b. Zonisamide in the treatment of headache disorders [abstract]. Cephalalgia, 21:374.
117. Krusz J, Scott V. 1999. Topiramate in the treatment of chronic migraine and other headaches [abstract). Headache, 39:363.
118. Krymchantowski AV, Bigal ME, Moreira PF. 2002. New and emerging prophylactic agents for migraine. CNS Drugs, 16:611-34.
119. Lampl C, Buzath A, Klinger D, et al. 1999. Lamotrigine in the prophylactic treatment of migraine aura - a pilot study. Cephalalgia, 19:58-63.
120. Lance JW, Anthony M, Somerville B. 1970. Comparative trial of serotonin antagonists in the management of migraine. Br Med J, 2:327-30.
121. Lance JW, Fine RD, Curran PA. 1963. An evaluation of methysergide in the prevention of migraine and other vascular headaches. Med J Aust, 50:814-8.
122. Landy S, McGinnis J, Curlin D, et al. 1999. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache, 39:28-32.
123. Lange R, Schwarz JA, Hohn M. 2000. Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia, 20:663-7.
124. Langohr HD, Gerber WD, Koletzki E, et al. 1985. Clomipramine and metoprolol in migraine prophylaxis - a double-blind crossover study. Headache, 25:107-13.
125. Langohr HP, Reinecke M, Gerber WD, et al. 1988. [Dihydroergotamine and flunarizine in the prevention of migraine. A comparative double-blind study]. Fortschr Med, 106:65-6, 69-70.
126. Lanteri-Minet M. 2005. What do patients want from their acute migraine therapy? Eur Neurol, 53 (Suppl 1):3-9.
127. Lanteri-Minet M, Alchaar H, Besson G, et al. 2000. [Pharmaco-epidemiological study on the prophylactic treatment of migraine. National inquiry on attitude to prescription practices by primary care physicians and neurologists in Franceo]. Rev Neurol (Paris), 156:1106-12.
128. Lanteri-Minet M, Auray JP, El Hasnaoui A, et al. 2003. Prevalence and description of chronic daily headache in the general population in France. Pain, 102:143-9.
129. Leandri M, Rigardo S, Schizzi R, et al. 1990. Migraine treatment with nicardipine. Cephalalgia, 10:111-6.
130. Leniger T, Pageter L, Stude P, et al. 2005. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache, 45:42-6.
131. Lewis DW, Kellstein D, Dahl G, et al. 2002. Children's ibuprofen suspension for the acute treatment of pediatric migraine. Headache, 42:780-6.
132. Lichten EM, Lichten JB, Whitty A, et al. 1996. The confirmation of a biochemical marker for women's hormonal migraine: the depo-estradiol challenge test. Headache, 36:367-71.
133. Limmroth V, Katsarava Z, Fritsche G, et al. 2002. Features of medication overuse headache following overuse of different acute headache drugs. Neurology, 59:1011-4.
134. Linde K, Rossnagel K. 2004. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev, 3:CD003225.
135. Linton-Dahlof P, Linde M, Dahlof C. 2000. Withdrawal therapy improves chronic daily headache associated with long-term misuse of headache medication:a retrospective study. Cephalalgia, 20:658-62.
136. Lipton RB, Cutrer FM, Goadsby PJ, et al. 2005a. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. Curr Med Res Opin, 21:413-24.
137. Lipton RB, Goldstein J, Baggish JS, et al. 2005b. Aspirin is efficacious for the treatment of acute migraine. Headache, 45:283-92.
138. Lipton RB, Stewart WF, Cady R, et al. 2000a. 2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache, 40:783-91.
139. Lipton RB, Stewart WF, Ryan RE Jr., et al. 1998. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol, 55:210-7.
140. Lipton RB, Stewart WF, Stone AM, et al. 2000b. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA, 284:2599-605.
141. Littleton-Kearney MT, Agnew PM, Traystman RJ, et al. 2000. Effects of estrogen on cerebral blood flow and pial microvasculature in rabbits. Am J Physiol Heart Circ Physiol, 279:H1208-14.
142. Loder EW, Buse DC, Golub JR. 2005. Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice. Headache, 45:224-31.
143. Lofland JH, Nash DB. 2005. Oral serotonin receptor agonists: a review of their cost effectiveness in migraine. Pharmacoeconomics, 23:259-74.
144. Louis P, Schoenen J, Hedman C. 1985. Metoprolol v. clonidine in the prophylactic treatment of migraine. Cephalalgia, 5:159-65.
145. Lu SR, Fuh JL, Chen WT, et al. 2001. Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia, 21:980-6.
146. Lucas C, Chaffaut C, Artaz MA, et al. 2005. FRAMIG 2000: medical and therapeutic management of migraine in France. Cephalalgia, 25:267-79.
147. Lucking CH, Oestreich W, Schmidt R, et al. 1988. Flunarizine vs propranolol in the prophylaxis of migraine: two double-blind comparative studies in more than 400 patients. Cephalalgia, (8 Suppl) 8:21-6.
148. Ludin HP. 1989. Flunarizine and propranolol in the treatment of migraine. Headache, 29:219-24.
149. Lyngberg AC, Rasmussen BK, Jorgensen T, et al. 2005. Prognosis of migraine and tension-type headache: a population-based follow-up study. Neurology, 65:580-5.
150. MacGregor EA. 2004. Oestrogen and attacks of migraine with and without aura. Lancet Neurol, 3:354-61.
151. MacGregor EA, Dowson A, Davies PT. 2002. Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache, 42:249-55.
152. MacGregor EA, Frith A, Ellis J, et al. 2006. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology, 67:2159-63.
153. MacGregor EA, Hackshaw A. 2002. Prevention of migraine in the pill-free interval of combined oral contraceptives: a double-blind, placebo-controlled pilot study using natural oestrogen supplements. J Fam Plann Reprod Health Care, 28:27-31.
154. Maissen CP, Ludin HP. 1991. [Comparison of the effect of 5-hydroxytryptophan and propranolol in the interval treatment of migraine]. Schweiz Med Wochenschr, 121:1585-90.
155. Martinez HR, Londono O, Cantu-Martinez L, et al. 2003. Topiramate as an adjunctive treatment in migraine prophylaxis. Headache, 43:1080-4.
156. Martucci N, Manna V, Mattesi P, et al. 1983. Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation. Cephalalgia, 3(Suppl 1):151-5.
157. Massiou H, Serrurier D, Lasserre O, et al. 1991. Effectiveness of oral diclofenac in the acute treatment of common migraine attacks: a double-blind study versus placebo. Cephalalgia, 11:59-63.
158. Mathew NT. 1993. Transformed migraine. Cephalalgia, 13 Suppl 12:78-83.
159. Mathew NT. 1997. Transformed migraine, analgesic rebound, and other chronic daily headaches. Neurol Clin, 15:167-86.
160. Mathew NT, Kailasam J, Meadors L. 2002. Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate. Headache, 42:796-803.
161. Mathew NT, Kailasam J, Meadors L, et al. 2000. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache, 40:720-3.
162. Mathew NT, Rapoport A, Saper J, et al. 2001. Efficacy of gabapentin in migraine prophylaxis. Headache, 41:119-28.
163. Mathew NT, Saper JR, Silbetstein SD, et al. 1995. Migraine prophylaxis with divalproex. Arch Neurol, 52:281-6.
164. Mathew NT, Stubits E, Nigam MP. 1982. Transformation of episodic migraine into daily headache: analysis of factors. Headache, 22:66-8.
165. McCarthy BG, Peroutka SJ. 1989. Comparative neuropharmacology of dihydroergotamine and sumatriptan (GR 43175). Headache, 29:420-2.
166. McEwen BS. 2001. Invited review: Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol, 91:2785-801.
167. Mei D, Capuano A, Vollono C, et al. 2004. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol Sci, 25:245-50.
168. Micieli G, Cavallini A, Marcheselli S, et al. 2001. Alpha-dihydroergocryptine and predictive factors in migraine prophylaxis. Int J Clin Pharmacol Ther, 39:144-51.
169. [MINES] Migraine-Nimodipine European Study Group. 1989a. European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Headache, 29:639-42.
170. [MINES] Migraine-Nimodipine European Study Group. 1989b. European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Headache, 29:633-8.
171. Monro P, Swade C, Coppen A. 1985. Mianserin in the prophylaxis of migraine: a double-blind study. Acta Psychiatr Scand Suppl, 320:98-103.
172. Montastruc JL, Senard JM. 1992. [Calcium channel blockers and prevention of migraine]. Pathol Biol (Paris), 40:381-8.
173. Mulleners WM, Chronicle EP, Vredeveld JW, et al. 2002. Visual cortex excitability in migraine before and after valproate prophylaxis: a pilot study using TMS. Eur J Neurol, 9:35-40.
174. Myllyla VV, Havanka H, Herrala L, et al. 1998. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache, 38:201-7.
175. Nachit-Ouinekh F, Dartigues JF, Chrysostome V, et al. 2005. Evolution of migraine after a 10-year follow-up. Headache, 45:1280-7.
176. Nebe J, Heier M, Diener HC. 1995. Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia, 15:531-5.
177. Neuman M, Demarez JP, Harmey JL, et al. 1986. Prevention of migraine attacks through the use of dihydroergotamine. Int J Clin Pharmacol Res, 6:11-3.
178. Noone JF. 1980. Clomipramine in the prevention of migraine. J Int Med Res, 8(Suppl 3):49-52.
179. Oldman AD, Smith LA, McQuay HJ, et al. 2002. Pharmacological treatments for acute migraine: quantitative systematic review. Pain, 97:247-57.
180. Olesen J. 1990. Calcium antagonists in migraine and vertigo. Possible mechanisms of action and review of clinical trials. Eur Neurol, 30(Suppl 2):31-4; discussion 39-41.
181. Olsson JE, Behring HC, Forssman B, et al. 1984. Metoprolol and propranolol in migraine prophylaxis: a double-blind multicentre study. Acta Neurol Scand, 70:160-8.
182. Orholm M, Honore PF, Zeeberg I. 1986. A randomized general practice group-comparative study of femoxetine and placebo in the prophylaxis of migraine. Acta Neurol Scand, 74:235-9.
183. Osterman PO. 1977. A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol (Divascan) in migraine prophylaxis. Acta Neurol Scand, 56:17-28.
184. Ozyalcin SN, Talu GK, Kiziltan E, et al. 2005. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache, 45:144-52.
185. Pascual J, Caminero AB, Mateos V, et al. 2004. Preventing disturbing migraine aura with lamotrigine: an open study. Headache, 44:1024-8.
186. Pascual J, Leira R, Lainez JM. 2003. Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia, 23:961-2.
187. Pedersen E, Moller CE. 1966. Methysergide in migraine prophylaxis. Clin Pharmacol Ther, 7:520-6.
188. Peroutka SJ, Lyon JA, Swarbrick J, et al. 2004. Efficacy of diclofenac sodium softgel 100 mg with or without caffeine 100 mg in migraine without aura: a randomized, double-blind, crossover study. Headache, 44:136-41.
189. Pfaffenrath V. 1993. Efficacy and safety of percutaneous estradiol vs placebo in menstrual migraine. Cephalalgia, 13(Suppl 13):244.
190. Pradalier A, Dry J, Loisy B, et al. 1988. [Comparative study of indoramin versus dihydroergotamine in the preventive treatment of migraine]. Therapie, 43:293-7.
191. Pradalier A, Lanteri-Minet M, Geraud G, et al. 2004a. The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care. CNS Drugs, 18:1149-63.
192. Pradalier A, Vincent D, Beaulieu P. 2004b. Correlation between oestradiol plasma level and therapeutic effect on menstrual migraine. In: Rose F (Ed.) New Advances in Headache Research. 4th Edition. London, UK: Smith-Gordon.
193. Rampello L, Alvano A, Chiechio S, et al. 2004. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology, 50:322-8.
194. Rao BS, Das DG, Taraknath VR, et al. 2000. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India, 48:223-6.
195. Reveiz-Herault L, Cardona AF, Ospina EG, et al. 2003. [Effectiveness of flunarizine in the prophylaxis of migraine: a meta-analytical review of the literature]. Rev Neurol, 36:907-12.
196. Rompel H, Bauermeister PW. 1970. Aetiology of migraine and prevention with carbamazepine (Tegretol): results of a double-blind, cross-over study. S Afr Med J, 44:75-80.
197. Ryan RE. 1968. Double-blind crossover comparison of bc-105, methysergide and placebo in the prophylaxis of migraine headache. Headache, 8:118-26.
198. Ryan RE, Sr. 1984. Comparative study of nadolol and propranolol in prophylactic treatment of migraine. Am Heart J, 108:1156-9.
199. Sandrini G, Franchini S, Lanfranchi S, et al. 1998. Effectiveness of ibuprofen-arginine in the treatment of acute migraine attacks. Int J Clin Pharmacol Res, 18:145-50.
200. Santucci M, Cortelli P, Rossi PG, et al. 1986. L-5-hydroxytryptophan
201. Saper JR, Silberstein SD, Lake AE, 3rd, et al. 1995. Fluoxetine and migraine: comparison of double-blind trials. Headache, 35:233.
202. Scher AI, Stewart WF, Liberman J, et al. 1998. Prevalence of frequent headache in a population sample. Headache, 38:497-506.
203. Scher AI, Stewart WF, Lipton RB. 2004. Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology, 63:2022-7.
204. Scher AI, Stewart WF, Ricci JA, et al. 2003. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain, 106:81-9.
205. Schuaib A, Ahmed F, Muratoglu M, et al. 1999. Topiramate in migraine prophylaxis: a pilot study [abstract]. Cephalalgia, 19:379-80.
206. Sculpher M, Millson D, Meddis D, et al. 2002. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. Pharmacoeconomics, 20:91-100.
207. Shekelle RB, Ostfeld AM. 1964. Methysergide in the Migraine Syndrome. Clin Pharmacol Ther, 5:201-4.
208. Shulda R, Garg RK, Nag D, et al. 1995. Nifedipine in migraine and tension headache: a randomised double blind crossover study. J Assoc Physicians India, 43:770-2.
209. Silberstein S, Merriam G. 1999. Sex hormones and headache 1999 (menstrual migraine). Neurology, 53:S3-13.
210. Silberstein SD. 1998. Methysergide. Cephalalgia, 18:421-35.
211. Silberstein SD. 2000. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 55:754-62.
212. Silberstein SD, Goadsby PJ. 2002. Migraine: preventive treatment. Cephalalgia, 22:491-512.
213. Silberstein SD, Neto W, Schmitt J, et al. 2004. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol, 61:490-5.
214. Silberstein SD, Winner PK, Chmiel JJ. 2003. Migraine preventive medication reduces resource utilization. Headache, 43:171-8.
215. Silvestrini M, Bartolini M, Coccia M, et al. 2003. Topiramate in the treatment of chronic migraine. Cephalalgia, 23:820-4.
216. Siniatchkin M, Gerber WD, Vein A. 1998. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study. Funct Neurol, 13:47-56.
217. Snow V, Weiss K, Wall EM, et al. 2002. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med, 137:840-9.
218. Solomon GD. 1989. Verapamil in migraine prophylaxis-a five-year review. Headache, 29:425-7.
219. Solomon S, Lipton RB, Newman LC. 1992. Clinical features of chronic daily headache. Headache, 32:325-9.
220. Somerville BW. 1972. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology, 22:355-65.
221. Somerville BW. 1975. Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology, 25:239-44.
222. Somerville BW, Carey HM. 1970. The use of continuous progestogen contraception in the treatment of migraine. Med J Aust, 1:1043-5.
223. Somerville BW, Herrmann WM. 1978. Migraine prophylaxis with Lisuride hydrogen maleate - a double blind study of Lisuride versus placebo. Headache, 18:75-9.
224. Sorensen PS, Larsen BH, Rasmussen MJ, et al. 1991. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache, 31:650-7.
225. Steardo L, Bonuso S, Di Stasio E, et al. 1982. Selective and non-selective beta-blockers: are both effective in prophylaxis of migraine? A clinical trial versus methysergide. Acta Neurol (Napoli), 4:196-204.
226. Steardo L, Marano E, Barone P, et al. 1986. Prophylaxis of migraine attacks with a calcium-channel blocker: flunarizine versus methysergide. J Clin Pharmacol, 26:524-8.
227. Steiner TJ, Alimed F, Findley LJ, et al. 1998. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia, 18:283-6.
228. Steiner TJ, Findley LJ, Yuen AW. 1997. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia, 17:109-12.
229. Steiner TJ, Joseph R, Hedman C, et al. 1988. Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up. Headache, 28:15-23.
230. Stellar S, Ahrens SP, Meibohm AR, et al. 1984. Migraine prevention with timolol. A double-blind crossover study. JAMA, 252:2576-80.
231. Stensrud P, Sjaastad O. 1979. Clonazepam (rivotril) in migraine prophylaxis. Headache, 19:333-4.
232. Stensrud P, Sjaastad O. 1980. Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine. Headache, 20:204-7.
233. Storey JR, Calder CS, Hart DE, et al. 2001. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache, 41:968-75.
234. Stronks DL, Tulen JH, Bussmann HB, et al. 2003. Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: a randomized, double-blind, double-dummy, crossover study. Headache, 43:845-52.
235. Sudilovsky A, Elkind AH, Ryan RE Sr., et al. 1987. Comparative efficacy of nadolol and propranolol in the management of migraine. Headache, 27:421-6.
236. Tanen DA, Miller S, French T, et al. 2003. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med, 41:847-53.
237. Tfelt-Hansen P, Block G, Dahlof C, et al. 2000. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia, 20:765-86.
238. Tfelt-Hansen P, Henry P, Mulder LJ, et al. 1995. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet, 346:923-6.
239. Tfelt-Hansen P, Olesen J. 1984. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia, 4:107-11.
240. The Diclofenac-K/Sumatriptan Migraine Study Group. 1999. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia, 19:232-40.
241. [TOSAM] The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. 1992. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol, 32:177-84.
242. Titus F, Davalos A, Alom J, et al. 1986. 5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine. Randomized clinical trial. Eur Neurol, 25:327-9.
243. Tomkins GE, Jackson JL, O'Malley PG, et al. 2001. Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med, 111:54-63.
244. Tomson T, Battino D. 2005. Teratogenicity of antiepileptic drugs: state of the art. Curr Opin Neurol, 18:135-40.
245. Ulrich V, Gervil M, Fenger K, et al. 1999. The prevalence and characteristics of migraine in twins from the general population. Headache, 39:173-80.
246. Vilming S, Standnes B, Hedman C. 1985. Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine. A double-blind investigation. Cephalalgia, 5:17-23.
247. Von Seggern RL, Mannix LK, Adelman JU. 2002. Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis. Headache, 42:804-9.
248. Wang SJ, Fuh JL, Lu SR, et al. 2000. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology, 54:314-9.
249. Wasserfallen JM. 1976. [Double-blind study with oxetorone in cephalalgia (author's transl)]. Schweiz Rundsch Med Prax, 65:1021-4.
250. Weber RB, Reinmuth OM. 1972. The treatment of migraine with propranolol. Neurology, 22:366-9.
251. Welch KM. 2003. Contemporary concepts of migraine pathogenesis. Neurology, 61:S2-8.
252. Wide K, Winbladh B, Kallen B. 2004. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr, 93:174-6.
253. Young WB, Hopkins MM, Shechter AL, et al. 2002. Topiramate: a case series study in migraine prophylaxis. Cephalalgia, 22:659-63.
254. Young WB, Siow HC, Silberstein SD. 2004. Anticonvulsants in migraine. Curr Pain Headache Rep, 8:244-50.
255. Zeeberg I, Orholm M, Nielsen JD, et al. 1981. Femoxetine in the prophylaxis of migraine - a randomised comparison with placebo. Acta Neurol Scand, 64:452-9.
256. Zivadinov R, Willheim K, Sepic-Grahovac D, et al. 2003. Migraine and tension-type headache in Croatia: a population-based survey of precipitating factors. Cephalalgia, 23:336-43.
257. Zwart JA, Dyb G, Hagen K, et al. 2003. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology, 61:160-4.